Severe methemoglobinemia from topical anesthetic spray: case report, discussion and qualitative systematic review

Riyad B. Abu-Laban, MD, MHSc;* Peter J. Zed, BSc (Pharm), PharmD;† Roy A. Purssell, MD;* Kenneth G. Evans, MD‡

Case report

A 56-year-old woman was urgently transferred from an outpatient endoscopy suite to our emergency department (ED) because of severe cyanosis and chest pain. She was a smoker and had a history of alcohol abuse, seizures, coronary artery disease and chronic obstructive pulmonary disease. Her medications included beclomethasone, ipratropium bromide and salbutamol, all administered by inhaler. She had no known allergies or drug sensitivities and no history of congestive heart failure.

The patient presented to the endoscopy suite at 1040, 2 hours and 20 minutes before her eventual transfer to the ED. At that time she felt completely well and had an oxy-
gen saturation of 97% by pulse oximetry. She was premedicated with a single oropharyngeal spray of 20% benzocaine (Hurricane Spray), as well as topical oropharyngeal lidocaine spray (4 metered doses of 10 mg/dose) and intravenous diazepam (15 mg). The procedure, an esophageal dilatation, was uneventful.

The patient was taken to the recovery room at 1135, 45 minutes after the premedication drugs were given. Within 5 minutes, she became agitated and hypoxic, with an oxygen saturation of 89% by pulse oximeter. Oxygen and nebulized salbutamol were administered, but her condition deteriorated, and profound cyanosis developed despite administration of high-flow oxygen. She then began to experience chest pain and was given nitroglycerin, 0.6 mg sublingual, followed by morphine 1 mg intravenously (IV). An electrocardiogram (ECG) showed nonspecific ST changes, and the chest x-ray was unremarkable. At this point she was transferred urgently to the ED with a presumptive diagnosis of pulmonary embolism or myocardial infarction.

On arrival in the ED at 1300, the patient was severely distressed and had profound cyanosis despite administration of 100% oxygen. She reported continuous, burning, nonradiating central chest pain unrelated to respirations, position or movement, for which she was given serial doses of sublingual nitroglycerin spray. She denied abdominal or extremity pain.

On examination, her pulse was 120 beats/min, respiratory rate 32 breaths/min and blood pressure 118/62 mm Hg. Oxygen saturation was 90% by pulse oximetry, and she was confused, with a score of 14 on the Glasgow Coma Scale. Air entry was normal and symmetric, with fine bibasal crepitations. Heart sounds were normal without murmurs, and her abdomen was soft and nontender. Examination of the extremities revealed no edema and no evidence of deep vein thrombosis. The musculoskeletal and nervous systems were normal.

At this time, a repeat ECG showed T-wave inversions in leads V1, V2 and V3, with (less than 1 mm of) ST elevation in leads V1, V2 and V3. Arterial blood gas analysis revealed a pH of 7.40, P(O2) of 342 mm Hg, P(CO2) of 37 mm Hg and oxygen saturation of 47% by co-oximeter. Because of the unexpectedly high P(O2) in the face of profound cyanosis, and the discordance between the pulse oximeter and co-oximeter saturation values, carboxyhemoglobin and methemoglobin levels were immediately performed, revealing values of 0% and 51% respectively. Ten minutes after the patient’s arrival, methylene blue was ordered — stat — and following a 20-minute delay to acquire the drug from the pharmacy, 140 mg (2 mg/kg) was administered IV over 5 minutes.

Within 10 minutes, the patient’s colour improved, and she appeared less distressed. Repeat arterial blood gas testing at 1345 revealed a pH of 7.31, P(O2) of 52 mm Hg, P(CO2) of 29 mm Hg and an oxygen saturation of 74% by co-oximeter. The methemoglobin level had fallen to 15%. Over the next 45 minutes, however, the patient’s status worsened dramatically with the development of severe respiratory distress, profound acidosis and pulmonary edema consistent with adult respiratory distress syndrome (ARDS). Furosemide 40 mg IV was administered, and she was endotracheally intubated in rapid-sequence fashion after the administration of fentanyl (250 µg), midazolam (5 mg) and succinylcholine (120 mg). She received intravenous atropine (1 mg) and epinephrine (3 doses of 0.1 mg) because of episodic bradycardia and hypotension, then was transferred to the intensive care unit (ICU). She remained intubated in the ICU for 12 days and received repeat doses of methylene blue during the early phase of her stay. There was no ECG or enzyme evidence of myocardial infarction, and she was discharged from the hospital without neurologic or cardiorespiratory sequelae 18 days after her initial presentation to the ED. On follow-up evaluations the patient remained well.

Discussion

Hemoglobin and methemoglobin

Hemoglobin is comprised of 4 heme groups, each containing an iron atom. Each atom is capable of binding oxygen, but such binding can occur only if the iron is in the reduced state (Fe(2+)). Removal of an electron from a reduced iron atom (oxidation: Fe(2+) to Fe(3+)) produces methemoglobin, which is incapable of binding oxygen. Moreover, the production of a ferric (Fe(3+)) heme group interferes with oxygen unloading by the other ferrous (Fe(2+)) heme groups on the hemoglobin moiety. This causes the oxyhemoglobin curve to shift to the left.1

Under physiologic circumstances methemoglobin is continuously produced as a result of the oxidizing effect of oxygen; however, it is rapidly converted back to hemoglobin, predominantly by cytochrome-b5 reductase (a.k.a. NADH-dependent methemoglobin reductase). As a result, methemoglobin levels are normally less than 2%. Five g/dL of deoxyhemoglobin is required to produce cyanosis, but because of the spectrographic properties of methemoglobin, the latter compound produces visible skin discoloration at a level of only 1.5 g/dL.1

Rare forms of congenital methemoglobinemia exist, but most cases of methemoglobinemia in adults are secondary to drugs or toxic agents. The most commonly used drugs that cause methemoglobinemia are benzocaine, lidocaine, pri-
locaine, dapsone, amyl nitrate, isobutyl nitrate, nitroglycerin, nitroprusside, primaquine, sulfonamides and phenazopyridine. It is not generally appreciated that therapeutic doses of most local anesthetics (given topically or intravenously) can produce this condition. In the case presented, methemoglobinemia was clearly due to the topical local anesthetic, as the only other new agent that the patient received was diazepam, a drug not associated with the condition.

Diagnosis
The definitive diagnostic test for methemoglobinemia is multiple-wavelength co-oximetry. Co-oximeters measure the light absorption of blood at numerous ultraviolet wavelengths. As a result, these machines are able to determine the percentages of oxyhemoglobin, deoxyhemoglobin, carboxyhemoglobin and methemoglobin. A multiple-wavelength co-oximeter is different from a pulse oximeter, which measures ultraviolet absorption at only two wavelengths (940 and 660 nm) to differentiate oxyhemoglobin and deoxyhemoglobin.4 Pulse oximeters are designed for continuous noninvasive monitoring, whereas co-oximeters require a blood sample and are typically available only at tertiary care centres.

A standard blood gas machine will not detect methemoglobin. Such machines measure oxygen tension (Po2) and pH, then calculate oxygen saturation from these values. This approach assumes the absence of abnormal hemoglobin. To complicate matters, pulse oximeters are unreliable in the presence of methemoglobin, because methemoglobin is detected by both the oxyhemoglobin (940 nm) and deoxyhemoglobin (660 nm) sensors of the oximeters. At low levels (<20%), methemoglobin is detected primarily by the deoxyhemoglobin sensor, and a pulse oximeter may show a falsely low oxygen saturation. At high methemoglobin levels (>70%), detection by the oxyhemoglobin sensor predominates, and a pulse oximeter may show a falsely high reading.2 Of note, methylene blue, the antidote for methemoglobinemia, is also detected by the pulse oximeter’s deoxyhemoglobin sensor, which leads to the potential for falsely low post-treatment oxygen saturation readings.2 One group of investigators compared oxygen saturation measurements by multiple-wavelength co-oximetry and pulse oximetry at various methemoglobin levels in a canine group of investigators compared oxygen saturation measurements by multiple-wavelength co-oximetry and pulse oximetry at various methemoglobin levels in a canine model.3 They found that pulse oximeter measurements overestimated oxygen saturation and that as the methemoglobin level rose, the pulse oximeter became increasingly insensitive to changes in oxygen saturation. In the case we have presented, pulse oximetry readings were falsely reassuring (90%) despite a methemoglobin level of 51%.

Because multiple-wavelength co-oximetry is not universally available, emergency physicians should be aware of other clinical findings and laboratory tests suggestive of methemoglobinemia. Clinical findings include cyanosis that is unresponsive to oxygen and cyanosis in the presence of normal (calculated) oxygen saturation. Although pulse oximeter readings are inaccurate in this circumstance, oximeter saturation values that deviate substantially from the clinical picture may suggest the diagnosis. In addition, if the difference between the calculated oxygen saturation from a standard blood gas machine and the reading from a pulse oximeter is greater than 5%, it is likely that the patient has an abnormal hemoglobin (either carboxyhemoglobin, methemoglobin or sulfhemoglobin; cyanohemoglobin does not result in this finding). Some authors refer to this as a “saturation gap,” whereas others use this term for the difference between the calculated oxygen saturation from a standard blood gas machine and the measured value from a co-oximeter. Detection of the first type of saturation gap can be clinically useful; detection of the latter type is less so, because availability of a co-oximeter measurement implies the ability to directly measure methemoglobin.

Although unexpected pulse oximeter readings may prompt consideration of the diagnosis of methemoglobinemia, oximeters should not be assumed to be accurate; nor should they be used to monitor patients if abnormal hemoglobins are suspected or confirmed. Moreover, if a saturation gap is found, it will not necessarily be proportional to the actual methemoglobin level (for example, a pulse oximeter saturation of 85% does not imply that the methemoglobin level is only 15%).

Treatment
Symptomatic patients with methemoglobinemia, particularly those with levels over 20%, should receive methylene blue, which acts as a cofactor for the enzyme NADPH methemoglobin reductase. Electrons are transferred from NADPH to methylene blue, which leads to a reduction of the heme iron, in the form of deoxyhemoglobin (Fig. 1). Methylene blue should not be administered to patients with severe glucose-6-phosphate dehydrogenase (G6PD) deficiency. These patients have low levels of NADPH, so methylene blue is ineffective and will cause hemolysis. There is no easily accessible laboratory test for G6PD deficiency; thus, when possible, patients should be directly asked about this condition.

Methylene blue should be administered at an initial dose of 1 to 2 mg/kg (0.1 to 0.2 mL/kg of a 1% solution) over 3 to 5 minutes, followed by a 15- to 30-mL fluid flush.4 5 Resolution of cyanosis usually occurs within 20 minutes. If there is no response and the patient has serious symptoms,
a repeat 1 mg/kg dose may be administered after 30 to 60 minutes. Side effects of methylene blue include bluish skin discoloration (complicating the assessment of cyanosis), hemolysis, gastrointestinal distress, bladder irritation and, ironically, methemoglobinemia (particularly in doses above 7 mg/kg). Failure to respond to methylene blue may reflect an incorrect diagnosis (e.g., sulfhemoglobinemia), inadequate gastrointestinal decontamination with ongoing toxin absorption, G6PD deficiency, congenital NADPH methemoglobin reductase deficiency, or a unique toxin such as analine or dronar (which cause prolonged absorption and cyclic methemoglobin production), phenylhydroxylamine (which blocks methylene blue uptake) or hydroxylamine (which blocks methylene blue uptake and inhibits NADPH methemoglobin reductase). In selected cases of unresponsive methemoglobinemia, the use of hyperbaric oxygen or exchange transfusion may be warranted.5 In the patient described, the cyanosis and methemoglobin level improved rapidly after administration of methylene blue; however, the development of ARDS, presumably from prolonged pulmonary hypoxia, led to a worsening of the clinical status.

Qualitative systematic review

To evaluate the described experience with methemoglobinemia secondary to topical anesthetic agents, we performed a qualitative systematic review of the English literature. We reviewed the electronic databases of MEDLINE (January 1966 to August 2000) and EMBASE (January 1988 to August 2000) using the search terms “methemoglobinemia,” “topical administration,” “anesthetic,” “benzocaine” and “lidocaine.” The reference lists from reports obtained from this search were hand searched to identify additional papers. All reports describing adults (over 18 years of age) with methemoglobinemia caused by topical anesthesia were reviewed and summarized by a single author (P.J.Z.).

Thirty-seven papers describing 44 cases met our inclusion criteria.6-42 The cases involved 30 men and 14 women from 24 to 84 years of age. The causative agent was Hurracaine Spray (benzocaine 20%) in 25 cases; Cetacaine (benzocaine 14% with tetracaine 2%) in 10 cases; a mixture of benzocaine spray (14% or 20%) with a viscous or spray lidocaine formulation in 5 cases; and benzocaine topical cream, gel or gargle in 3 cases. In one case the agent was not specified. Most cases involved esophagoscopy, bronchoscopy or endotracheal intubation.

In 41 cases involving topical spray, symptoms developed within 20 minutes of administration in 30 cases (73%), within 60 minutes in 36 cases (88%), and within 2 hours in 100% of cases. Methemoglobin concentrations ranged from 19% to 75%, and one death, from irreversible shock 24 hours after the onset of symptoms, was reported. Cyanosis was present in all cases. Other clinical findings reported included agitation, confusion, headache, dizziness, weakness, dyspnea, epigastric pain and hypotension. In 2 cases, ECG

---

![Fig. 1. Methemoglobin production and action of methylene blue](https://www.cambridge.org/core/terms). Downloaded from https://www.cambridge.org/core, IP address: 54.70.40.11, on 31 May 2019 at 16:22:35, subject to the Cambridge Core terms of use, available at https://www.cambridge.org/core/terms. https://doi.org/10.1017/S1481803500005182
evidence of myocardial ischemia was reported. Many of the case reports noted a poor correlation between pulse oximeter and co-oximeter readings. Methylene blue was administered as a single IV dose of 1 to 2 mg/kg in 36 (82%) of the 44 cases. In 4 cases, a benzocaine rechallenge led to a recurrence of methemoglobinemia.11,33,37,41

Conclusions

The case of methemoglobinemia we presented is consistent with others described in the literature, although the associated chest pain (likely from myocardial ischemia) and ARDS (likely from pulmonary hypoxia) were unique. Since all previously described cases of methemoglobinemia from topical anesthetic involved benzocaine, and because there is no compelling evidence for the role of lidocaine as a solo inducer, we conclude that this case was almost certainly due to the benzocaine spray.

It is clear from this case and the literature reviewed that therapeutic doses of topical anesthetic agents can cause methemoglobinemia. It is also clear from our discussions with other emergency physicians that most are unaware of this important fact. This topic is highly relevant to emergency medicine. EDs often stock benzocaine as an alternative agent for lidocaine-allergic patients and because of its more palatable taste. Emergency physicians frequently use topical anesthetic agents for awake intubation and direct or indirect laryngoscopy. In addition, patients who receive these agents for procedures in outpatient areas of the hospital are likely to be transferred to the ED if problems develop, as happened in the case presented. As a result, it is important for emergency physicians to be aware of this serious idiosyncratic reaction and to have knowledge of the presentation, diagnosis and treatment of methemoglobinemia. Finally, as our case illustrates, the time delay to acquire drugs from a hospital pharmacy can certainly be a factor in critical situations; thus, we feel that methylene blue should be among the antidotes immediately available in the ED. To reduce delays in administration, our ED has added to ward stock sufficient methylene blue for an initial 2 mg/kg dose.

Acknowledgement: The authors thank Dr. Jeffrey Brubacher for his assistance in the preparation of this paper.

References


Correspondence to: Dr. Riyad B. Abu-Laban, Department of Emergency Medicine, Vancouver General Hospital, 855 W 12th Ave., Vancouver BC V5Z 1M9; abulaban@interchange.ubc.ca.